<DOC>
	<DOC>NCT02383940</DOC>
	<brief_summary>This Phase 2 study is intended to demonstrate superiority of Sotagliflozin versus placebo on A1C reduction at Week 12 in young adult patients with T1DM who have poor glycemic control on their current insulin regimen.</brief_summary>
	<brief_title>Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<criteria>Patient has given written informed consent Young adult patients ≥18 to ≤30 years old at Screening, with a confirmed diagnosis of T1DM made at least 1 year prior to informed consent Patients are being treated with insulin or insulin analogue delivered via CSII or MDI At Screening, must have A1C ≥9.0% Must be willing and able to perform SMBG and complete the study diary Females of childbearing potential must use an adequate method of contraception and have a negative pregnancy test Any prior use of LX4211/Sotagliflozin Use of antidiabetic agent other than insulin or insulin analogue at the time of screening Use of SGLT inhibitors within 8 weeks prior to start of the placebo Runin Period Chronic systemic corticosteroid use Type 2 diabetes, or severely uncontrolled diabetes mellitus as determined by the Investigator History of DKA or nonketotic hyperosmolar state within 6 months prior to the Screening Visit History of severe hypoglycemic event within 1 month prior to Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>